Hypoxia News and Research

RSS

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.

SwitchGear Genomics introduces high-throughput research tools for profiling biological pathway regulation

SwitchGear Genomics, Inc., a leading provider of products for studying regulatory elements in the human genome, today announced the availability of the first cost-effective, high-throughput research tools for screening transcriptional activation and repression in a number of key biological pathways.

14 Oct 2009

Aeolus Pharmaceuticals raises $1.65 million from existing institutional shareholders

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the “Units”), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.

7 Oct 2009

NOAA awards $457,000 grant to track and manage outbreaks of toxic red tide algae

NOAA has awarded $457,000 in competitive grant funding to support three projects to better track and manage outbreaks of toxic red tide algae that threaten public health and New England's shellfish industry. The grant covers the first year of what will be multi-year projects. Anticipated to cost almost $1.5 million over the next three years, they will be carried out by the Woods Hole Oceanographic Institution, the University of Maine and the University of Texas.

5 Oct 2009

Januvia in combination with metformin or taken alone lowers blood sugar

A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two years.

29 Sep 2009

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

King Pharmaceuticals(R), Inc. (NYSE: KG) today announced a true milestone as it marks the first commercial availability for EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

21 Sep 2009

Project to study the generation and movement of harmful algal blooms

NOAA and the National Science Foundation have awarded $824,225 in competitive funds for the first year of an anticipated four-year $2.8 million project to develop early warning forecast models for toxic harmful algal blooms, or HABs, on Pacific Northwest beaches. Funds were awarded to the University of Washington and the University of California at Santa Cruz through the interagency Ecology and Oceanography of Harmful Algal Blooms (ECOHAB) program.

18 Sep 2009

Aeolus commences second study of AEOL 10150 against Acute Radiation Syndrome

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today the initiation of a second study, in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS) in the lungs. This study, led by Zeljko Vujaskovic, M.D. Ph.D. of Duke University, is designed to build on the recently completed study that demonstrated the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation, and determine the most effective duration of delivery for treatment after exposure.

14 Sep 2009

AOLS to initiate clinical study for testing the efficacy of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that it has initiated a study to confirm the efficacy of AEOL 10150 as a countermeasure to nuclear and radiological exposure in non-human primates.

9 Sep 2009

Spectrum's ZEVALIN expanded label receives FDA approval for treating non-Hodgkin’s Lymphoma

Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN® (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S. Food and Drug Administration (FDA) for an expanded label for the treatment of patients with previously untreated follicular non-Hodgkin’s Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.

5 Sep 2009

Scientists demonstrate the link between cancer and diesel fumes

Scientists here are the first to demonstrate that the link between diesel fume exposure and cancer lies in the ability of diesel exhaust to induce the growth of new blood vessels that serve as a food supply for solid tumors.

2 Sep 2009

New compound discovered by Scripps scientists offers a novel template for drug development

Scientists at Scripps Institution of Oceanography at UC San Diego and their colleagues at Creighton University have deciphered the highly unusual molecular structure of a naturally produced, ocean-based compound that is giving new understanding of the function of mammalian nerve cells.

29 Aug 2009

Chk1 and Fbx6 play an important role for the regulation of response to chemotherapy

Cell cycle checkpoints act like molecular tripwires for damaged cells, forcing them to pause and take stock. Leave the tripwire in place for too long, though, and cancer cells will press on regardless, making them resistant to the lethal effects of certain types of chemotherapy, according to researchers at the Salk Institute for Biological Studies.

28 Aug 2009

Joseph Finn announces inclusion of PRX-08066 therapeutics program in Phase 2 for respiratory indication

Joseph F. Finn, Jr., C.P.A. , announced today that the PRX-08066 Therapeutics Program in Phase 2 for respiratory indication will be part of the intellectual property offered for sale at the September 30, 2009 auction.

19 Aug 2009

Oxygen nanosensor could improve tumor imaging

A new material developed at the University of Virginia - an oxygen nanosensor that couples a light-emitting dye with a biopolymer - simplifies the imaging of oxygen-deficient regions of tumors. Such tumors are associated with increased cancer aggressiveness and are particularly difficult to treat.

11 Aug 2009

Two significant advances in treating lung cancer

Dr. Glen Weiss of the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare this week announced two significant advances in treating lung cancer at an international cancer research conference.

7 Aug 2009

Research looks at cellular stress response to low oxygen

Gary Chiang, Ph.D., and colleagues at Burnham Institute for Medical Research (Burnham) have elucidated how the stability of the REDD1 protein is regulated. The REDD1 protein is a critical inhibitor of the mTOR signaling pathway, which controls cell growth and proliferation.

5 Aug 2009

Divers who hold breath for several minutes elevate a marker for brain damage

Divers who held their breath for several minutes had elevated levels of a protein that can signal brain damage, according to a new study from the Journal of Applied Physiology. However, the appearance of the protein, S100B, was transient and leaves open the question of whether lengthy apnea (breath-holding) can damage the brain over the long term.

4 Aug 2009

Epigenetic signature changes in low oxygen levels may contribute to prostate cancer development

UCD Conway researchers have characterised epigenetic signature changes in prostate cells under conditions of low oxygen levels that may lead to tumour development.

30 Jul 2009

Deferoxamine could help diabetics heal wounds

A drug used to remove iron from the body could help doctors fight one of diabetes' cruelest complications: poor wound healing, which can lead to amputation of patients' toes, feet and even legs.

28 Jul 2009

Protein regulates movement of mitochondria in brain cells

Scientists have identified a protein in the brain that plays a key role in the function of mitochondria - the part of the cell that supplies energy, supports cellular activity, and potentially wards off threats from disease.The discovery, which was reported today in the Journal of Cell Biology, may shed new light on how the brain recovers from stroke.

15 Jun 2009